CDT Conduit Pharmaceuticals Inc: Earnings per share for the last 12 months

Public company logo of Conduit Pharma (CDT)

Conduit Pharmaceuticals (CDT) is developing a translational medicine platform, creating selective kinase inhibitors for kidney therapy. The 12-month EPS growth trend captures the current trajectory, where the parameter is 98.80. This results from integrating promising molecules into new research and utilizing a mid-stage asset acquisition model, which minimizes operational risks and eliminates dependence on business cycles.

Conduit Pharma (CDT): Net earnings per share for the last 12 months from 11/23/2025 to 11/15/2026

CDT (Conduit Pharmaceuticals Inc): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Share Price Conduit Pharmaceuticals Inc|CDT - Price Target Chart
- company stock capitalization data:
Market Capitalization Conduit Pharma|CDT - Enterprise Value
- book capitalization indicators:
Net Asset Value per Share Conduit Pharmaceuticals|CDT - Company Net Assets|Market-to-Book Ratio conduitpharma.com|CDT - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Conduit Pharmaceuticals|CDT - Long-Term Debt to Equity|Current Liabilities to Capital conduitpharma.com|CDT - Company Debts|Debt to Book Value Ratio Conduit Pharma|CDT - Company Long-Term Debts|Company Short-Term Indebtedness Conduit Pharmaceuticals|Quick Ratio conduitpharma.com
- net income and valuation ratios data:
CDT - Net Profit|Company Profit Forecast Conduit Pharmaceuticals|CDT - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Conduit Pharmaceuticals|CDT - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Conduit Therapeutics|CDT - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Conduit Pharmaceuticals|CDT - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months conduitpharma.com|CDT - Earnings growth in current year|Earnings growth forecast for next year Conduit Pharmaceuticals
- sales volume and revenue information:
CDT - Company Revenue|Company Future Revenue Conduit Pharmaceuticals Inc|CDT - Price-to-Revenue Ratio|Forward Price-to-Revenue Multiple Conduit Pharma|CDT - Sales Growth YoY (TTM)
Initial company analysis:Conduit Pharmaceuticals Inc., CDT
Manufactured product of Conduit Pharmaceuticals Inc.

The stable operation of Conduit Pharmaceuticals (CDT) R&D centers in synthesizing new molecules lays the foundation for future capitalization. The EPS YoY TTM growth value reflects the dynamics of net income per share over the last twelve months relative to the previous year. This indicator measures the efficiency of converting laboratory capacities into actual financial results. Analyzing the trajectory of this metric allows for an assessment of the business scaling pace. The asset is categorized as a high-risk speculative instrument.

Competitor analysis for Conduit Pharmaceuticals

Net earnings per share for the last four quarters Travere Therapeutics, Inc. TVTX|ARDX: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months PROK|Earnings per share for the last twelve months Akebia Therapeutics, Inc.|Earnings per share for the last 12 months TVRD (Cara Therapeutics Inc)|Net earnings per share (EPS TTM) DMAC|UNCY - Net earnings per one share for the last twelve months|rockwellmed.com - Net earnings per share for the last 12 months|Cadrenal Therapeutics, Inc (CVKD) - Net earnings per one share for the last twelve months|Calliditas Therapeutics AB - Net earnings per share (EPS TTM)|Earnings per share for the trailing year RNLX (renalytix.com)|ZVSA (zyversa.com) - Net earnings per share for the last 12 months